Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 8/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064885 | 0.86 | ACE (0.43) | ACENR1D1POLBTDP1L3MBTL1 | |
| SCHEMBL17838137 | 0.85 | OPRM1 (0.43) | ACENR1D1POLBTDP1L3MBTL1 | |
| SCHEMBL17559495 | 0.83 | BCL2 (0.47) | ACENR1D1POLBTDP1L3MBTL1 | |
| SCHEMBL17559498 | 0.83 | BCL2 (0.47) | ACENR1D1POLBTDP1L3MBTL1 | |
| SCHEMBL4595358 | 0.83 | BCL2 (0.47) | ACENR1D1POLBTDP1L3MBTL1 | |
| SCHEMBL4783225 | 0.81 | OPRM1 (0.53) | ACENR1D1OPRM1OPRD1OPRK1 | |
| SCHEMBL28826000 | 0.81 | OPRM1 (0.43) | ACENR1D1POLBOPRM1OPRL1 | |
| SCHEMBL25378557 | 0.78 | OPRM1 (0.56) | ACENR1D1POLBOPRM1OPRD1 | |
| SCHEMBL28056722 | 0.78 | OPRM1 (0.56) | ACENR1D1POLBOPRM1OPRD1 | |
| SCHEMBL16417180 | 0.78 | ACE (0.41) | ACENR1D1POLBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | ACE 4185/4885NR1D1 2957/4885POLB 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.